UltraClear Laser
Provider Portal | For Patients | Find a Provider Service 866.222.5276 Sales 888.833.0399
UltraClear Laser
  • Technology
    • UltraClear®
    • 3DMIRACL®
    • Laser-Coring™
    • Provider Testimonials
  • Results
    • Results Gallery
    • Submit Your Results
  • Resources
    • Clinical Publications
    • Committed To Your Success
    • Webinars on Demand
    • Find a Provider
    • Blogs
  • Media
    • Press Releases
    • In The News
    • Videos
  • Events
  • About
  • Contact
  • Service 866-222-5276
  • Sales 888-833-0399
Select Page

Clinical Publications

Download any of our featured publications below.
Single Treatment Multi-Pass Advanced Resurfacing with Fractional Ablative 2910 nm Fiber Laser & Fiber Enabled Laser-Coring: A Case Series

Single Treatment Multi-Pass Advanced Resurfacing with Fractional Ablative 2910 nm Fiber Laser & Fiber Enabled Laser-Coring: A Case Series

read more
Advancing Aesthetic Laser Medicine Full Ablation Resurfacing Outcomes with the 2910 nm Fiber Laser: A Case Series Demonstrating Safety and Efficacy

Advancing Aesthetic Laser Medicine Full Ablation Resurfacing Outcomes with the 2910 nm Fiber Laser: A Case Series Demonstrating Safety and Efficacy

read more
Clinical evaluation of a new fractional ablative 2910 nm erbium laser on photodamaged skin: A pilot study

Clinical evaluation of a new fractional ablative 2910 nm erbium laser on photodamaged skin: A pilot study

read more
Single treatment scar resurfacing with a novel ablative fractional 2910 nm erbium-doped fluoride glass fiber laser

Single treatment scar resurfacing with a novel ablative fractional 2910 nm erbium-doped fluoride glass fiber laser

read more
The 2910-nm Fiber Laser Is Safe and Effective for Improving Acne Scarring

The 2910-nm Fiber Laser Is Safe and Effective for Improving Acne Scarring

read more
Histological analysis of laser-enabled tissue coring with a novel 2910 nm erbium-doped fluoride glass fiber laser

Histological analysis of laser-enabled tissue coring with a novel 2910 nm erbium-doped fluoride glass fiber laser

read more
Low-fluence treatment with a novel fractionated 2,910-nm fiber laser improves photodamage

Low-fluence treatment with a novel fractionated 2,910-nm fiber laser improves photodamage

read more
Characterizing Laser-Induced Wound Healing Dynamics Using Line-Field Confocal Optical Coherence Tomography

Characterizing Laser-Induced Wound Healing Dynamics Using Line-Field Confocal Optical Coherence Tomography

read more
Full‐face and neck resurfacing with a novel ablative fractional 2910nm erbium‐doped fluoride glass fiber laser for advanced photoaging

Full‐face and neck resurfacing with a novel ablative fractional 2910nm erbium‐doped fluoride glass fiber laser for advanced photoaging

read more

888.833.0399

hello@acclaromd.com

  • Follow
  • Follow
  • Follow
  • Follow
Find a Provider
Download the Brochure

Technology

UltraClear®
3DMIRACL®
Laser-Coring™
Provider Testimonials

Results

Results Gallery
Submit Your Results

Resources

Clinical Publications
Commited To Your Success
Webinars On Demand
Find A Provider
Blogs
Events

Media

Press Releases
In the News
Videos

© 2026 Acclaro Medical. All Rights Reserved. UltraClear and CoolPulse™ are registered trademarks. The information available on this website is provided for informational purposes only. This information is not intended to replace a medical consultation where a physician’s judgment may advise you about specific disorders, conditions, and/or treatment options. We hope the information will be useful for you to become more educated about your healthcare decisions. In case you’re experiencing visual impairment or any other condition that is protected under the Americans with Disabilities Act or a law akin to it, and you’re interested in discussing accommodations to enhance your experience with this website, kindly get in touch with our Accessibility Manager at 888.833.0399. Sitemap | Privacy Policy | Terms of Use

¹ benign cosmetic keratosis *Through a presumed mechanism of action of collagen remodeling.